WO2015023967A3 - Compositions and methods for modulating dna methylation - Google Patents

Compositions and methods for modulating dna methylation Download PDF

Info

Publication number
WO2015023967A3
WO2015023967A3 PCT/US2014/051317 US2014051317W WO2015023967A3 WO 2015023967 A3 WO2015023967 A3 WO 2015023967A3 US 2014051317 W US2014051317 W US 2014051317W WO 2015023967 A3 WO2015023967 A3 WO 2015023967A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
dna methylation
modulating dna
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/051317
Other languages
French (fr)
Other versions
WO2015023967A2 (en
Inventor
Timothy Darren EUBANK
Clay Braden Marsh
Duaa DAKHLALLAH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2016534872A priority Critical patent/JP2016529257A/en
Priority to US14/911,380 priority patent/US20160199434A1/en
Priority to RU2016109125A priority patent/RU2016109125A/en
Priority to CA2921005A priority patent/CA2921005A1/en
Priority to HK16111814.3A priority patent/HK1223508A1/en
Priority to CN201480057009.4A priority patent/CN105979779A/en
Priority to MX2016002014A priority patent/MX2016002014A/en
Priority to KR1020167006500A priority patent/KR20160046832A/en
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Priority to EP14835786.6A priority patent/EP3032953A4/en
Priority to AU2014306496A priority patent/AU2014306496A1/en
Publication of WO2015023967A2 publication Critical patent/WO2015023967A2/en
Publication of WO2015023967A3 publication Critical patent/WO2015023967A3/en
Priority to IL244082A priority patent/IL244082A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein are compositions and methods for modulating DNA methylation of one or more gene promoters, treating a subject diagnosed with or suspected of having a disease or disorder characterized by DNA hypermethylation, decreasing c-myc expression, increasing desmoplakin expression, and inhibiting metastases.
PCT/US2014/051317 2013-08-16 2014-08-15 Compositions and methods for modulating dna methylation Ceased WO2015023967A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2016002014A MX2016002014A (en) 2013-08-16 2014-08-15 Compositions and methods for modulating dna methylation.
RU2016109125A RU2016109125A (en) 2013-08-16 2014-08-15 COMPOSITIONS AND METHODS OF MODULATION OF DNA METHYLING
CA2921005A CA2921005A1 (en) 2013-08-16 2014-08-15 Compositions and methods for modulating dna methylation
HK16111814.3A HK1223508A1 (en) 2013-08-16 2014-08-15 Compositions and methods for modulating dna methylation
CN201480057009.4A CN105979779A (en) 2013-08-16 2014-08-15 Compositions and methods for modulating DNA methylation
KR1020167006500A KR20160046832A (en) 2013-08-16 2014-08-15 Compositions and methods for modulating dna methylation
EP14835786.6A EP3032953A4 (en) 2013-08-16 2014-08-15 Compositions and methods for modulating dna methylation
JP2016534872A JP2016529257A (en) 2013-08-16 2014-08-15 Compositions and methods for modulating DNA methylation
US14/911,380 US20160199434A1 (en) 2013-08-16 2014-08-15 Compositions and methods for modulating dna methylation
AU2014306496A AU2014306496A1 (en) 2013-08-16 2014-08-15 Compositions and methods for modulating DNA methylation
IL244082A IL244082A0 (en) 2013-08-16 2016-02-11 Compositions and methods for modulating dna methylation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361867000P 2013-08-16 2013-08-16
US61/867,000 2013-08-16

Publications (2)

Publication Number Publication Date
WO2015023967A2 WO2015023967A2 (en) 2015-02-19
WO2015023967A3 true WO2015023967A3 (en) 2015-04-09

Family

ID=52468818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/051317 Ceased WO2015023967A2 (en) 2013-08-16 2014-08-15 Compositions and methods for modulating dna methylation

Country Status (12)

Country Link
US (1) US20160199434A1 (en)
EP (1) EP3032953A4 (en)
JP (1) JP2016529257A (en)
KR (1) KR20160046832A (en)
CN (1) CN105979779A (en)
AU (1) AU2014306496A1 (en)
CA (1) CA2921005A1 (en)
HK (1) HK1223508A1 (en)
IL (1) IL244082A0 (en)
MX (1) MX2016002014A (en)
RU (1) RU2016109125A (en)
WO (1) WO2015023967A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2686520T3 (en) 2011-06-06 2018-03-17
HUE066123T2 (en) 2013-06-13 2024-07-28 Akebia Therapeutics Inc Compositions and methods for treating anemia
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US20180051345A1 (en) 2015-03-06 2018-02-22 Vib Vzw Markers for Determining Tumor Hypoxia
NZ735973A (en) 2015-04-01 2023-06-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
CN108048529B (en) * 2017-12-28 2021-01-19 广州市金圻睿生物科技有限责任公司 Quality control product of lung cancer methylation gene detection kit capable of being stably stored and application
EP3770256A4 (en) * 2018-03-20 2021-12-22 Tokyo Institute of Technology OLIGONUCLEOTIDE ANTISENS WITH REDUCED TOXICITY
CN108441561A (en) * 2018-04-19 2018-08-24 安徽达健医学科技有限公司 A kind of dual kit of the fluorescence quantitative PCR method for the detection of carcinoma of urinary bladder early screening that methylate
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2020092862A1 (en) * 2018-11-01 2020-05-07 The Jackson Laboratory Dlgap2 as a therapeutic target for and alzheimer's disease and age-related cognitive decline
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
CN113122634B (en) * 2020-01-14 2026-03-10 江苏鹍远生物科技股份有限公司 Reagent for detecting DNA methylation and application thereof
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
JP7863050B2 (en) * 2020-05-14 2026-05-20 エイアールアイズィー・プリシジョン・メディスン・インコーポレイテッド Cancer therapy that modulates PRDM2/RIZ protein expression using siRNA
CN117965739A (en) * 2024-02-21 2024-05-03 中山大学附属第一医院 Markers, primer combinations and applications for cervical cancer-related gene methylation detection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100331374A1 (en) * 2006-06-26 2010-12-30 Shengde Wu Prolyl hydroxylase inhibitors and methods of use
US20120329836A1 (en) * 2011-06-06 2012-12-27 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
US20130022974A1 (en) * 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012268380C1 (en) * 2011-06-06 2017-03-23 Nationwide Children's Hospital, Inc. Proteomics based diagnostic detection method for chronic sinusitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100331374A1 (en) * 2006-06-26 2010-12-30 Shengde Wu Prolyl hydroxylase inhibitors and methods of use
US20120329836A1 (en) * 2011-06-06 2012-12-27 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
US20130022974A1 (en) * 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU ET AL.: "Hypoxia Induces Genomic DNA Demethylation through the Activation of HIF. 1 alpha and Transcriptional Upregulation of MAT2A in Hepatoma Cells.", MOL CANCER THER, vol. 10, June 2011 (2011-06-01), pages 1113 - 1123, XP055318661 *
YANG ET AL.: "Desmoplakin acts as a tumor suppressor by inhibition of the Wnt/beta-catenin signaling pathway in human lung cancer.", CARCINOGENESIS, vol. 33, no. 10., 12 July 2012 (2012-07-12), pages 1863 - 1870, XP055318663 *

Also Published As

Publication number Publication date
MX2016002014A (en) 2016-07-21
KR20160046832A (en) 2016-04-29
HK1223508A1 (en) 2017-08-04
US20160199434A1 (en) 2016-07-14
EP3032953A2 (en) 2016-06-22
CN105979779A (en) 2016-09-28
JP2016529257A (en) 2016-09-23
AU2014306496A1 (en) 2016-03-03
IL244082A0 (en) 2016-04-21
RU2016109125A (en) 2017-09-22
EP3032953A4 (en) 2017-02-08
CA2921005A1 (en) 2015-02-19
WO2015023967A2 (en) 2015-02-19
RU2016109125A3 (en) 2018-07-30

Similar Documents

Publication Publication Date Title
MX2016002014A (en) Compositions and methods for modulating dna methylation.
WO2014035140A3 (en) Compounds and compositions for modulating histone methyltransferase activity
EP3236973A4 (en) Rna agents for gst-pi gene modulation
EP3294671A4 (en) Enhanced biochar
BR112015000671A2 (en) biorefinery system, methods and compositions thereof.
PL3425055T3 (en) Molecular detection/diagnosis reagent for tumor
EP2672967A4 (en) COMPOUNDS AND METHODS FOR MODULATING KINASE, AND INDICATIONS THEREOF
CL2015001341S1 (en) Sidebar protector
EP3019994A4 (en) Analyzing target software for security vulnerabilities
BR112015004815A2 (en) sealing member, tamper evident seal and liner, and tamper evident seal.
BR112014001258A2 (en) dna typing method, and primer sets for dna typing
EP3190889A4 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP3257292A4 (en) Pathway-based data interruption detection
WO2014116833A3 (en) Compositions and methods for detecting neoplasia
EP3095055A4 (en) Biopsy-driven genomic signature for prostate cancer prognosis
EP3377658A4 (en) Modified nucleotide reagents
HK1209328A1 (en) Compositions and methods for treating type iii gaucher disease
WO2014036040A3 (en) Methods for diagnosis, prognosis and methods of treatment
EP3121205A4 (en) Acrylamide polymer, paper strength enhancing agent, and paper
EP3079680A4 (en) Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders
EP3798316A3 (en) Genes and gene signatures for diagnosis and treatment of melanoma
BR112015013152A2 (en) composition for treating an underground formation, method for treating an underground formation, and method for reducing the viscosity of crude oil.
EP3239183A4 (en) Modified conjugated diene polymer, and polymer composition containing said polymer
EP3163301A4 (en) Method for diagnosing, treating, or preventing mood disorder
EP3052662A4 (en) Compositions, systems and methods for gene expression noise drug screening and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14835786

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2921005

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14911380

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 244082

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2016534872

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/002014

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2014306496

Country of ref document: AU

Date of ref document: 20140815

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20167006500

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014835786

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016109125

Country of ref document: RU

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14835786

Country of ref document: EP

Kind code of ref document: A2